Agathos Biologics Launches Analytical Services

Initial offerings focus on high-content imaging and digital PCR Agathos Biologics, a leading biotechnology company, is proud to offer advanced analytical testing services for life science researchers.

Initial offerings focus on high-content imaging and digital PCR

FARGO, N.D.--(BUSINESS WIRE)-- Agathos Biologics, a leading biotechnology company, is proud to offer advanced analytical testing services for life science researchers. With a focus on high-content imaging and digital PCR, our team of experienced scientists use state-of-the-art technology to deliver unparalleled accuracy and reliability in nucleic acid quantification and cell analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230411005720/en/

Fluorescence (left) and digital phase contrast (right) images of sheep kidney cells (Photo: Business Wire)

Fluorescence (left) and digital phase contrast (right) images of sheep kidney cells (Photo: Business Wire)

The first of its kind within the region, Agathos’ high-content imaging services allow the capture and analysis of multiple parameters within a cell, providing a more comprehensive understanding of biology than ever before. With various imaging applications, including immunohistochemistry, immunofluorescence, and signaling pathways, our experienced scientists can now offer the best imaging experiments available.

Agathos Biologics uses the latest digital PCR (dPCR) technology, delivering unparalleled sensitivity and precision in nucleic acid quantification. dPCR methods can detect and quantitate low concentrations of target nucleic acid sequences with high accuracy, making it a powerful tool for mutation analysis, viral vector titer determination, and pathogen detection. Agathos exclusively uses QIAcuity instrumentation and assays from QIAGEN and has collaborated with QIAGEN in mycoplasma and recombinant adeno-associated viral vector (rAAV) assay testing and validation.

“Our goal is to advance biotechnology and genetic medicine with products and services through ethical innovation,” said James Brown, CEO and co-founder of Agathos. “As we develop capabilities for our internal research and development, we have the opportunity to make these high-content imaging and digital PCR services available to clients in our region and beyond. These services represent the first step in our strategy to create breakthrough products and services within a strong ethical and moral framework that benefit everyone.” For more information on high-content imaging and dPCR, visit Agathos Services on our web site.

About Agathos

Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as The Good Science Company is to create breakthrough products and services within a strong ethical and moral framework that benefit everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visit www.agathos.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005720/en/

Contacts

James Brown, Ph.D.
CEO
james.brown@agathos.bio
+1-701-415-3395

Source: Agathos Biologics

Smart Multimedia Gallery

Fluorescence (left) and digital phase contrast (right) images of sheep kidney cells (Photo: Business Wire)

Powered by Business Wire

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20230411005720/en

MORE ON THIS TOPIC